# REJOICE-PanTumor01 (NCT06660654)

> A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06660654
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Advanced Solid Tumor; Metastatic Solid Tumors
- Interventions: Raludotatug deruxtecan
- Enrollment: 335
- Primary outcome: Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
- Primary outcome: Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)
- Primary outcome: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 8
- Podcasts: 5
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rejoice-pantumor01-nct06660654

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06660654", "email": "<work email>"}; the inbox owner confirms by the emailed link.